Substance abuse in patients with schizophrenia

Dialogues in Clinical Neuroscience

Volumn 8, Issue 1, 2006, Pages 37-43

  Winklbaur, Bernadette ^a   Ebner, Nina ^a   Sachs, Gabriele ^a   Thau, Kenneth ^a   Fischer, Gabriele ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Comorbidity; Epidemiology; Intervention; Neurobiological aspects; Schizophrenia; Substance abuse

Indexed keywords

CANNABIS; CLOZAPINE; COCAINE; NICOTINE; OLANZAPINE; RISPERIDONE;

ALCOHOL ABUSE; ARTICLE; CANNABIS ADDICTION; CIGARETTE SMOKING; COCAINE DEPENDENCE; COMORBIDITY; DISEASE COURSE; HUMAN; NEUROBIOLOGY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREVALENCE; PSYCHOSIS; PSYCHOTHERAPY; RELAPSE; SCHIZOPHRENIA; SUBSTANCE ABUSE;

CANNABIS; COCAINE; HUMANS; NICOTINE; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 33646130395     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Dickey B, Azeni H, Weiss R, et al. Schizophrenia, substance use disorders and medical co-morbidity. J Ment Health Policy Econ. 2000;3:27-33.
2. Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D. Substance misuse in patients with schizophrenia. Drugs. 2002;62:743-755.
3. Munetz MR, Grande TP, Chambers MR. The incarceration of individuals with severe mental disorders. Community Ment Health J. 2001;37:361-372.
4. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcome. Schizophr Res. 1999;35:93-100.
5. Regier DA, Farmer ME, Donald SR, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990;264:2511-2518.
6. Shaner A, Khalsa ME, Roberts L, et al. Unrecognised cocaine use among schizophrenic patients. Am J Psychiatry. 1993;150:758-762.
7. Ziedonis D, Kosten T, Glazer W, Frances R. Nicotine dependence and schizophrenia. Hosp Community Psychiatry. 1994;45:204-206.
8. Brady KT, Sinha R. Co-occuring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry. 2005;162:1483-1493.
9. Linszen DH, Dingemans PM, Lenor ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51:273-279.
10. Alexander, MJ. Women with co-occurring addictive and mental disorders: an emerging profile of vulnerability. Am J Orthopsychiatry. 1996;66:61-70.
11. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.
12. Levin ED, Wilson W, Rose JE, et al. Nicotine haloperidol interactions and cognitive performance in schizophrenia. Neuropsychopharmacology. 1996;15:429-36.
13. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry. 1992;149:1189-1194.
14. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993;150:1856-1861.
15. Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biol Psych. 1996;40:1155-1163.
16. van Nimwegen L, de Haan L, van Beveren N, van den Brink W, Linszen D. Adolescence, schizophrenia and drug abuse: a window of vulnerability. Acta Psychiatr Scand. 2005;111(suppl 427):35-42.
17. Chambers R, Taylor J. Potenza M. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry. 2003;160:1041-1052.
18. Markou A, Kosten TR, Koob GF. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology. 1998;18:135-174.
19. Chambers RA, Krsytall JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry. 2001;50:71-83.
20. Juckel G, Schlagenhauf F, Koslowski M, et al. Dysfunction of central striatal reward prediction in schizophrenia. Neuroimage. 2005. (Epub ahead of print)
21. Heinz A, Reimold M, Wrase J, et al. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry. 2005;62:57-64.
22. Matholon DH, Pfefferbaum A, Lim KO, Rosenbloom MJ, Sullivan EV. Compounded brain volume deficits in schizophrenia-alcoholism comorbidity. Arch Gen Psychiatry. 2003;60:245-252.
23. Weiser M, Reichenberg A, Grotto I, et al. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry. 2004;161:1219-1223.
24. Andreasson S, Allebeck P, Engström, A, et al. Cannabis and schizophrenia: a longitudinal study of Swedish conscripts. Lancet. 1988;2:1483-1485.
25. Arsenault L, Cannon M, Poulton R, Murray R, Caspi Amoffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325:1212-1213.
26. Fergusson DM, Horwood LJ, Ridder EM. Test of causal linkages between cannabis use and psychotic symptoms. Addiction. 2005;100:354-366.
27. Arsenault L, Cannon M, Witton, J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004;184:110-117.
28. D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558-1572.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
30. Mirken B. The cannabis and psychosis connection questioned: a comment on Fergusson et al. Addiction. 2005;100:714-715.
31. Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction. 2004;99:425-430.
32. Sayers SL, Campell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis. 2005;193:379-386.
33. Green Al, Zimmet S, Strous R, Schildkraut J. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry. 1999;6:287-296.
34. Buckley P. Substance abuse in schizophrenia: a review. J Clin Psychiatry. 1998;3:26-26.
35. Beresford TP, Clapp L, Martin B, et al. Aripiprazole in schizophrenia with cocaine dependence. A pilot study. J Clin Psychopharmacol. 2005;25:363-366.
36. Kavanagh DJ, White A, Young R, et al. Towards an integrated and sensitive family intervention for comorbid substance abuse and schizophrenia: a comment on Sheils and Rolfe (2000). Aust J Fam Ther. 2000;21:88-90.
37. Graham H. The role of dysfunctional beliefs in individuals who experience psychosis and use substances: implications for cognitive therapy and medication adherence. Behav Cogn Psychother. 1998;26:193-208.
38. Kavanagh DJ, Young R, White A, et al. A brief motivational intervention for substance misuse in recent-onset psychosis. Drug Alcohol Rev. 2004;23:151-155.
39. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res. 1999;35:561-566.
40. Green AI. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin Psychiatry. 2005;66 (suppl 6):21-26.
41. Harvey PD, Green MF, Keefe RS, Velligan DI. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry. 2004;65:361-372.
42. Sachs G, Katschnig H. Cognitive dysfunction in schizophrenic psychoses. Drug and psychological treatment choices. Psychiatr Prax. 2001;28:60-68.
43. de Haan L, Lavalaye J, van Bruggen M, et al. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry. 2004;49:290-295.